RecruitingNCT05377307
Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy
Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pell Bio-Med Technology Co., Ltd.
- Principal Investigator
- Chen-Lung Lin, MDPell Bio-Med Technology Co., Ltd.
- Intervention
- Pell's lentiviral-based gene-edited immune cell therapy(genetic)
- Enrollment
- 49 enrolled
- Eligibility
- All sexes
- Timeline
- 2022 – 2037
Study locations (5)
- Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan, Taiwan
- National Taiwan University Hospital, Taipei, Taiwan, Taiwan
- Taipei Veterans General Hospital, Taipei, Taiwan, Taiwan
- Chi Mei Medical Center, Tainan, Taiwan
- Taipei Medical University - Taipei Medical University Hospital, Taipei, Taiwan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05377307 on ClinicalTrials.govOther trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07162012Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive LymphomaShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- RECRUITINGPHASE2NCT06846463Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+Virginia Commonwealth University
- RECRUITINGPHASE3NCT06929624A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell LymphomaSuzhou Suncadia Biopharmaceuticals Co., Ltd.
- RECRUITINGPHASE1NCT06830031Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell LymphomaShanghai Exuma Biotechnology Ltd.
- RECRUITINGNCT07198230Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell LymphomaTing YANG
- RECRUITINGPHASE2NCT07254754Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- RECRUITINGPHASE3NCT06522555The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRuijin Hospital
- RECRUITINGPHASE2NCT05934448Pembro Plus CAR T-cell Therapy in R/R in PMBCLJennifer Crombie, MD
See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma →